SEATTLE, July 20, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global castrate-resistant prostate cancer market is estimated to be valued at US$ 9.5 billion in 2021 and is expected to exhibit a CAGR of 8.2% during the forecast period (2021-2028).
Key Trends and Analysis of the Global Castrate-resistant Prostate Cancer Market:
Key trends in the market include increasing cases of prostate cancer, increasing number of product launches, and rising research and development activities.
The increasing prevalence of prostate cancer is expected to fuel growth of the global castrate-resistant prostate cancer market over the forecast period. For instance, according to the Cancer Research UK report 2018, the most common cancer in men is prostate cancer and over 47,500 men were diagnosed with prostate cancer accounting for 129 men each day, and death rate amounting to over 11,500 men across the U.K.
The increasing number of product approvals and launch is expected to bolster growth of the global castrate-resistant prostate cancer market. For instance, on May 15 2020, Clovis Oncology Inc., a biopharmaceutical company, announced that the U.S. Food and Drugs Administration (FDA) approved Rubraca (rucaparib) tablets for the treatment of adult patients with a deleterious BRCA (BReast CAncer gene) mutation -associated metastatic castration-resistant prostate cancer (mCRPC).
Request for Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4529
Moreover, increasing research and development activities for the treatment of castrate-resistant prostate cancer is expected to drive growth of the global castrate-resistant prostate cancer market. For instance, on May 29 2020, Pfizer Inc., a multinational pharmaceutical company and Astellas Pharma Inc., a Tokyo-based company in collaboration, announced the final results of the Phase 3 PROSPER trial's overall survival (OS) analysis. The final PROSPER results showed that XTANDI (enzalutamide) significantly extended overall survival in men with non-metastatic castration-resistant prostate cancer (nmCRPC).
Key Market Takeaways:
The increasing research and development activities, rising product launches and approvals, inorganic activities such as collaborations, acquisitions, and others are expected to drive growth of the global castrate-resistant prostate cancer market over the forecast period. For instance, on April 28, 2021, ESSA Pharma Inc., a clinical-stage pharmaceutical company, announced an agreement with Bayer AG, a multinational pharmaceutical & life sciences company. The agreement calls for ESSA's lead product candidate, EPI-7386 to be in combination with Bayer's darolutamide tested in patients with metastatic castration-resistant prostate cancer (‘mCRPC’).
Competitive Landscape:
Key players operating in the global castrate-resistant prostate cancer market include Sanofi, Johnson & Johnson Services Inc., Pfizer Inc., Astellas Pharma Inc., Bayer AG, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis International AG, Eli Lilly & Company, and AstraZeneca plc.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4529
Market Segmentation:
- Global Castrate-resistant Prostate Cancer Market, By Therapy Type:
- Hormonal Therapy
- Immunotherapy
- Chemotherapy
- Global Castrate-resistant Prostate Cancer Market, By Drug Class:
- Antineoplastic
- Non-steroidal Antiandrogen
- Corticosteroids
- Microtubule Inhibitor
- Others
- Global Castrate-resistant Prostate Cancer Market, By Route of Administration:
- Oral
- Injectable
- Global Castrate-resistant Prostate Cancer Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Castrate-resistant Prostate Cancer Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- North America
Related Market Intelligence Reports:
Cancer Biologics Market, by Product (Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, and Immune Checkpoint Inhibitors), by Application (Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, and Others), by Distribution Channel (Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Read more: https://www.coherentmarketinsights.com/ongoing-insight/cancer-biologics-market-4145
North America and Europe Minimally Invasive Prostate Cancer Surgery Market, By Product Type (Hand (Resectoscope, Linear Cutter, Insufflators, Curved Stapler, Endoscopic Trocars, Prostatic Retractor, Cryoablation Device, Others), Monitoring & Visualization (Cameras & Video Support, Endoscopic Trocars with Optical View), Powered (Electrosurgical Unit, Lasers)), By Application (Laparoscopy Robotics Surgery Brachytherapy Cryosurgery), and By Region (North America, Europe) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.